Loading clinical trials...
Loading clinical trials...
The incretin effect is impaired in patients with type 2 diabetes mellitus (T2DM), thus GLP-1 receptor agonists are used for the treatment of T2DM. Insulin resistance is a pathophysiologic hallmark of non-alcoholic fatty liver disease (NAFLD). The incretin effect in patients with NAFLD has not been studied. The aim of this study is to quantify GLP-1 secretion in response to oral glucose tolerance test (oGTT) in patients with NAFLD compared to healthy controls. The results of this study will expand the knowledge of the pathophysiology of NAFLD and serve as a rational for potential future treatment strategies.
Primary endpoint: GLP-1 response to oral glucose Secondary endpoints: glucose and insulin responses to oral glucose challenge
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
Yes
University Hospital Basel, Division of Gastroenterology and Hepatology
Basel, Switzerland
Start Date
January 1, 2011
Primary Completion Date
April 1, 2012
Completion Date
June 1, 2012
Last Updated
August 29, 2012
102
ACTUAL participants
Oral glucose tolerance test
OTHER
Lead Sponsor
University Hospital, Basel, Switzerland
NCT05574036
NCT06623539
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07104786